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Abstract
Background—Prostate cancer is the major cause of cancer death in men and the androgen
receptor (AR) has been shown to play a critical role in the progression of the disease. Our previous
reports showed that knocking down the expression of the AR gene using a siRNA-based approach
in prostate cancer cells led to apoptotic cell death and xenograft tumor eradication. In this study,
we utilized a biodegradable nanoparticle to deliver the therapeutic AR shRNA construct
specifically to prostate cancer cells.
Materials & methods—The biodegradable nanoparticles were fabricated using a poly(DL-lactic-
co-glycolic acid) polymer and the AR shRNA constructs were loaded inside the particles. The
surface of the nanoparticles were then conjugated with prostate-specific membrane antigen
aptamer A10 for prostate cancer cell-specific targeting.
Results—A10-conjugation largely enhanced cellular uptake of nanoparticles in both cell culture-
and xenograft-based models. The efficacy of AR shRNA encapsulated in nanoparticles on AR
gene silencing was confirmed in PC-3/AR-derived xenografts in nude mice. The therapeutic
property of A10-conjugated AR shRNA-loaded nanoparticles was evaluated in xenograft models
with different prostate cancer cell lines: 22RV1, LAPC-4 and LNCaP. Upon two injections of the
AR shRNA-loaded nanoparticles, rapid tumor regression was observed over 2 weeks. Consistent
with previous reports, A10 aptamer conjugation significantly enhanced xenograft tumor regression
compared with nonconjugated nanoparticles.
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Discussion—These data demonstrated that tissue-specific delivery of AR shRNA using a
biodegradable nanoparticle approach represents a novel therapy for life-threatening prostate
cancers.
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Prostate cancer is one of the major causes of cancer death among men in the USA [1].
Medical treatment for metastatic prostate cancer has relied heavily on androgen ablation.
Unfortunately, most patients treated by androgen ablation ultimately relapse to more
aggressive castration-resistant cancers [2]. The etiology of castration-resistant progression of
prostate cancers may have various molecular causes, but in most cases, androgen receptor
(AR) expression is maintained [3,4]. Recent studies have demonstrated that AR signaling is
required for prostate cancer progression [5–10]. Consistently, we and others have shown that
suppression of AR gene expression by siRNA-mediated AR gene silencing led to reduced
tumor growth in AR-positive prostate cancers [11–15]. Therefore, this AR siRNA-based
approach provides a powerful gene therapy for advanced prostate cancers.
Successful delivery of therapeutic agents efficiently and specifically to the target tissue/cell
is desirable for the treatment of human cancers. A current drug delivery hotspot is polymeric
nanoparticles (NPs), which do not have the side effects of traditional viral vectors (i.e.,
insertional mutagenesis and immunogenesis) or liposome vehicles (i.e., toxicity and
inefficiency). Properly designed NPs can be delivered specifically to a target tissue and the
encapsulated drug can then be released inside the targeted cells after degradation of the NP
matrix without affecting surrounding tissues [16,17]. Nanoparticles that have a hydrophilic
surface can avoid uptake by the reticuloendothelial system and passively accumulate in
tumors due to the enhanced permeability and retention effect in leaky tumor vasculature
[17,18]. Additional coatings (i.e., polyethylene glycol [PEG]) can further increase their
circulating time by repelling plasma proteins [18].
The prostate-specific membrane antigen (PSMA) is a well-known tumor antigen and it is
primarily expressed on the surface of prostate cancer epithelial cells and also has been
reported to be expressed on the tumor microvasculature and other organs and tissues [19,20].
This cell surface expression pattern and its elevated levels in metastatic prostate cancers
warranted it as a promising target for the diagnosis, detection and management of prostate
cancer [20]. As such, PSMA has currently been used for molecular imaging, cancer vaccine
development and targeted drug delivery in prostate cancers. In particular, a RNA-based
aptamer targeting human PSMA was developed (PSMA-A10), which interacts specifically
with the PSMA extracellular domain [21].
In order to maintain sustained gene silencing in cells, a common approach is to stably
transfect the cells with a hairpin-structured siRNA under the control of a promoter, such as
CMV, U6 or H1 RNA polymerase promoter [22]. Thus, we designed a hairpin structure
based on AR siRNA sequences and then generated an adeno-associated virus (AAV) that
bears the hairpin-structured AR siRNA (ARHP8) sequence [7,23]. Local or systemic
delivery of the AAV-ARHP8 virus to nude mice bearing human prostate cancer xenografts
abolished tumor growth regardless of their hormone responsiveness [13]. These previous
studies provide strong support for the therapeutic property of the AR siRNA-based strategy.
As a delivery vehicle for targeted therapy, NPs could be functionalized to have high tissue/
cell selectivity to avoid systemic side effects and long bloodstream circulating time to
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increase the efficiency of the delivered therapeutic agents. Over other polymers,
biodegradable poly-DL-lactic-co-glycolic acid (PLGA) offers advantages of being fully
biodegradable in vivo and has been approved for use in humans by the US FDA [24]. PSMA
aptamer-mediated prostate cancer cell-specific targeting has been demonstrated recently
[25–34]. Therefore, we developed a strategy using PSMA aptamer-conjugated PLGA NPs to
deliver the AR shRNA constructs for AR silencing. Our results demonstrated that this
strategy successfully delivered the AR shRNA constructs specifically into prostate cancer
cells, resulting in effective tumor eradication in vivo.
Materials & methods
Fabrication of PLGA-PEG-COOH NPs encapsulating the plasmid DNA
PLGA (50:50; inherent viscosity: 0.67 dl/g; molecular weight ~100 kDa) was purchased
from Absorbable Polymers (AL, USA). 2, 2, 2-trifluoro-ethanol was purchased from
ACROS (NJ, USA). Pluronic® F127 was purchased from Sigma-Aldrich (MO, USA).
Plasmid DNAs (pAAV-green fluorescent protein [GFP] and pAAVA-RHP8-GFP) were
purified using QIAGEN Giga kits. AR siRNA targeting sequence (5′-AAGAAGGC
CAGUUGUAUGGAC-3′) and AR shRNA construction (5′-GAAGGCCAGTTGTATG
GACttcaagagaGTCCATACAACTGGCCTTC-3′) were described in our previous reports
[7,23].
PLGA NPs were prepared by a solvent diffusion method. Briefly, 0.8 ml of 18 mg/ml PLGA
solution dissolved in 2, 2, 2-trifluoroethanol was mixed with 0.2 ml of DNA solution
containing 200–500 µg DNA dissolved in TE buffer (pH 8.0). The mixture was added to 10
ml 0.1% modified Pluronic® F127-COOH (the hydroxyl groups of Pluronic® F127 were
changed to carboxyl groups) through a syringe pump (17.5 ml/h) under stirring at 250 rpm.
The modified Pluronic® F127 was utilized as a surfactant to impart reactive carboxyl groups
on the particle surface. The NPs that were produced were dialyzed using a 1000 kDa
molecular weight cutoff membrane for 12–16 h, refreshing the dialysate twice.
Characterization of the size & surface charge of PLGA NPs
The sizes and zeta potentials of the PLGA NPs were determined using a ZetaPALS dynamic
light scattering system (ZetaPALS, Brookhaven Instruments Corp., NY, USA).
Conjugation of aptamer to PLGA NPs
A suspension of Pluronic® F127-COOH-coated PLGA NPs was buffered using 2-(N-
morpholino) ethanesulfonic acid, pH 6.5. Nanoparticles were then incubated with 100 mM
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 50 mM N-
hydroxysulfosuccinimide for 15 min. The activated carboxyl terminus of Pluronic® F127-
COOH on the surface of NPs was allowed to react with the amino terminus of the aptamer
(15 mM) for at least 6 h at room temperature. Conjugated NPs were dialyzed with purified
water. Size and charge of NP and aptamer-NP were characterized using dynamic light
scattering (ZetaPALS). The amount of free aptamer after the reaction was quantified by
reverse phase HPLC on a Vydac® Protein and Peptide C18 column with a gradient of 5–
90% acetonitrile over 30 min. The peaks were monitored by UV absorbance at 260 nm. The
density of aptamer on the surface of NPs was calculated from the total surface area assuming
a normal Guassian particle size distribution.
Determination of the plasmid DNA/aptamer entrapment efficiency & release from PLGA–
PEG NP formulations in vitro
Briefly, 500 µl of various NP suspensions was centrifuged. The pellet was washed three-
times using 1.5 ml water. Then, 500 µl chloroform was added to dissolve the pellet and 1 ml
Yang et al. Page 3













TE buffer (pH 8.0) was added to extract DNA from the organic phase. After centrifugation,
the UV absorbance at 260 nm was used to quantify DNA in the TE buffer phase (Table 1).
DNA/aptamer extraction was also visualized on a 1% agarose gel after ethidium bromide
staining.
Cell culture & cellular uptake of NPs in vitro
Human prostate cancer cell lines LAPC-4, LNCaP, 22RV1 and PC-3/AR were grown in the
conditions as described previously [7,13]. For assessing cellular uptake of NPs, cells were
plated in 12-well plates overnight and the suspension of NPs was added to the culture. At
designated time-points, cell nuclei DNA was stained with nuclear dye Hoechst 33324 for 5
min. The percentage of cells that displayed positive fluorescence were quantitatively
counted from five to ten microscopic fields and the representative micrographs were
acquired using a fluorescent microscope (Olympus, Japan).
RNA extraction, reverse transcription-PCR & western blot assays
Total RNA was extracted using TriZol™ reagent (Invitrogen, CA, USA) from cultured cells,
xenograft tissues and mouse organs. Reverse transcription (RT)-PCR was carried out using a
RETROscript™ kit (Ambion, TX, USA) to assess AR gene expression at the mRNA level.
The primers for the AR and S18 ribosome RNA were described in our recent publications
[7,13]. For quantitative PCR, a different pair of AR primers (forward: 5′-
GAAAGCGACTTCACCGCACCTG-3′; backward 5′-
ACATGGTCCCTGGCAGTCTCC-3′) was used. S18 primers was used as internal control.
For western blot analysis, protein samples were extracted from cell lysates or xenograft
tumors that were snap-frozen and stored at 80°C. Equal amounts of protein were subjected
to SDS-PAGE and then western blot for assessing AR expression. Actin blot served as a
protein-loading control. Antibodies for AR (clone 441) and actin were purchased from Santa
Cruz Biotechnology (CA, USA).
Animal xenograft model, DNA extraction & quantitative PCR
Athymic NCr-nu/nu male mice (NCI-Frederick, Fort Detrick, VA, USA) were maintained in
accordance with the Institutional Animal Care and Use Committee procedures and
guidelines. Xenograft tumors were established as described in our recent publication
[13,39]. Briefly, exponentially grown cells were trypsinized and resuspended in phosphate-
buffered saline. A total of 2.0 × 106 cells was resuspended in RPMI-1640/10% fetal bovine
serum with a 4:1 v/v ratio of Matrigel™ (BD Bioscience, MA, USA), and was injected
subcutaneously into the rear flanks or the dosal-lateral loops of the prostate. For
subcutaneous xenografts, when tumors were palpable (30–50 mm3 in 4–6 weeks), animals
were divided into different groups for treatment with NPs. As described in the legends of
Figures 1 & 2, NPs were injected systemically via tail vein. Tumor growth was monitored
by measuring the length (L) and the width (W), and the volume was calculated using
Equation 1:
(1)
For orthotropic xenograft models, blood samples were collected by tail incision and serum
prostate-specific antigen (PSA) levels were determined using a commercial ELISA kit
(Abnova, CA, USA). At necropsy, prostate loops were harvested and their wet weights were
recorded before snap-frozen.
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Western blot, fluorescent images and RT-PCR results were presented from a representative
experiment. The mean and standard error of the mean from cell counting and animal
experiments are shown. The differences between treatment and control groups were
analyzed using the SPSS software (SPSS, IL, USA).
Results
Preparation & characterization of plasmid DNA-loaded aptamer-conjugated PLGA NPs
Polymeric particles serve as a common carrier and controlled release delivery system for
DNA [24]. Many particle formation processes utilize harsh homogenization or
ultrasonication to disperse a solution of the polymer phase into an aqueous phase where
solvent extraction from the polymer phase takes place. The shear associated with these
processing conditions requires intensification to create increasingly smaller particle sizes,
often damaging plasmid DNA to linear or fragmented forms [35]. In this study, we utilized a
solvent diffusion technique that reduced shear and improved retention of DNA structure
[36–38]. Phenol/chloroform extraction assay revealed that PSMA aptamers were
successfully conjugated onto the surface of the PLGA NPs (Figure 3B).
Aptamer conjugation enhances AR shRNA-mediated gene silencing & cell death
As reported in our previous publication, AR silencing led to profound apoptotic cell death in
AR-native prostate cancer cells, and systemic delivery of the AR silencing viral particles
eradicated prostate cancer xenografts in nude mice [7,13]. Due to the safety concern of viral
vectors for clinical use, we developed a strategy that utilizes the PLGA-based NP to deliver
the AR shRNA construct.
First, we evaluated cellular uptake of the NPs with or without A10 aptamer. Nile-red
fluorescent dye was encapsulated into the NPs as an indicator of cellular uptake. PSMA-
positive human prostate cancer LNCaP cells were used for the testing. As shown in Figure 4,
A10 aptamer-conjugated NPs bound to cells more rapidly than the nonaptamer-conjugated
NPs in a dose- and time-dependent manner.
Next, we evaluated the cellular uptake in vivo using a mouse xenograft model derived from
human prostate cancer 22RV1 cells. As shown in Figure 4D, A10 aptamer-conjugated NPs
were uptaken by 22RV1 xenografts much faster and to a greater extent than nonaptamer-
conjugated NPs. These data are supported by previous reports showing that PSMA aptamer
conjugation exhibits strong, differential delivery to prostate cancer cells [25–34].
To determine the efficacy of A10 aptamer-conjugated NPs on plasmid DNA delivery for AR
gene silencing, we then used the A10-NPs to deliver ARHP8 constructs. We first tested
A10-NP-mediated AR gene silencing in LNCaP cells. A10-conjugated or naked (no A10
conjugation) NPs loaded with ARHP8 constructs were added into cell culture. Cells were
harvested 5 days later and total RNAs were extracted for RT-PCR assay. As shown in
Figure 5A, naked or A10-conjugated NPs loaded with GFP-expressing constructs had no
effect on AR gene expression. By contrast, ARHP8 construct-loaded NPs induced a
significant reduction of AR gene expression at the mRNA and protein levels compared with
the control, of which A10 conjugation dramatically enhanced the AR silencing effect.
Similar results were also obtained in LAPC-4 (Figure 5B). Quantitative RT-PCR also
revealed that A10 conjugation significantly enhanced ARHP8-induced AR gene silencing
(Figure 5C). These data indicated that the strategy using A10 PSMA aptamer-conjugated
NPs largely increases NP uptake, and the A10-conjugated PLGA NP is capable of delivering
AR shRNA plasmid vector for gene silencing.
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Aptamer-conjugated AR shRNA-loaded NPs eradicated xenograft tumors
Before testing the antitumor effect of NP-encapsulated ARHP8 shRNA in a large group
setting, we first performed a pilot animal study to determine the minimum dose of NPs for
efficient AR gene silencing in the xenograft tumors after intravenous injection. Mouse
subcutaneous xenograft tumors were established with PC-3/AR cells, which were described
in our previous publication [7]. Because PC-3 cells are PSMA negative, we used naked NPs
to deliver the ARHP8 plasmid. Meanwhile, since cell survival for PC-3 cells is not
dependent on AR gene expression, knocking down AR expression will not affect xenograft
tumor growth derived from PC-3 cells. When the tumor is palpable (~50 mm3 in 4–6
weeks), five different doses of NPs that contain 1.0, 2.0, 4.0, 6.0 or 8.0 µg ARHP8 plasmid
DNA were injected via tail vein into the animals. In addition, one animal received
phosphate-buffered saline as negative control. The tumors and other organs (liver, spleen,
kidney, testes, intestine and lung) were harvested 1 week later. Total RNA extracts from the
tumor samples were used to evaluate AR mRNA levels and protein extracts from tumor
tissues were used to assess AR protein expression by immunoblotting. As shown in Figures
6A & 6B, a dose-dependent reduction of AR expression at the mRNA and protein levels was
noticed and the effective dose for AR silencing was ≥4.0 µg plasmid DNA-loaded NPs,
which was then used in the following experiments. Tissue distribution of the NPs was
analyzed by PCR reactions for GFP sequence with the genomic DNA samples extracted
from xenograft tumors and various organs (Figure 6C), and the analysis revealed that most
of the NPs were retained in xenograft tumors, followed by prostate, liver, spleen, kidney and
testis. Since PC-3/AR cells are not dependent on functional AR to survive, injection of
ARHP8 NPs had no effect on tumor growth.
We next investigated the antitumor effect of the A10-conjugated ARHP8-encapsulated NPs
in a large group of xenograft-bearing nude mice. We used three cell lines, castration-
resistant 22RV1 cells, and androgen-responsive LAPC-4 and LNCaP to generate xenografts
in nude mice as described in our previous publication [39]. Once the tumors were palpable
(~30–50 mm3), animals received two tail vein injections of NPs with an interval of 1 week
(Figure 1). Tumor growth was monitored three-times a week. Due to the heavy burden of
xenograft tumors in the control groups, animals were sacrificed at day 21 (3 weeks) after the
first treatment. As shown in Figure 1A, injection of ARHP8-encapsulated NPs (Nano-
ARHP8) significantly reduced the tumor growth of 22RV1 xenografts compared with the
control NPs (Nano-GFP). In Nano-ARHP8-treated animals, xenograft tumors eventually
disappeared, which is similar to our previous finding when ARHP8 shRNA was delivered
with AAV approach [13]. Most importantly, however, treatment with A10-conjugated
ARHP8 NPs led to an even more rapid tumor eradication compared with the treatment with
naked ARHP8 NPs (14 days in A10-conjugated PLGA vs 17 days in naked PLGA). These
data are consistent with previous reports that PSMA aptamer conjugation enhances PLGA
NP-mediated ARHP8 transfection in prostate cancer cells [25–27].
Since the pioneer work from other groups demonstrated the efficacy of PSMA aptamer
(A10)-mediated prostate cancer cell targeting [29–32], we did not include naked PLGA NP
groups in our next animal studies but instead focused on the comparison of ARHP8-loaded
versus GFP-loaded A10-PLGA NPs. As seen in Figures 1B & 1C, in comparison with the
control GFP construct-loaded A10-PLGA NPs, treatment with ARHP8-loaded A10-PLGA
NPs led to a rapid regression of xenograft tumors derived from LAPC4 or LNCaP cells.
These data indicated that PLGA NPs represent a feasible approach to replace the AAV
strategy for ARHP8 construct delivery for in vivo AR silencing.
In addition, we tested the antitumor effect of Nano-ARHP8 with or without the PSMA
aptamer A10 conjugation in orthotopic xenograft model. LNCaP cells were inoculated in
nude mouse prostate (dorsal-lateral loops). Mouse serum levels of human PSA were
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monitored as a sign for tumor development. After 4 weeks, once the mouse serum PSA
reached 70–90 ng/ml, animals were divided into three groups and received different
treatments. As shown in Figure 2, serum PSA levels steadily increased in the control group
that received GFP NPs, representing a typical pattern of tumor growth in vivo. Conversely,
treatment with ARHP8-loaded PLGA NPs resulted in a dramatic decrease in serum PSA
level, indicating a rapid tumor regression. In comparison, treatment with A10-Nano-ARHP8
further enhanced the rapid decrease in serum PSA levels.
At the end of experiments, animals were sacrificed, the prostate loops together with seminal
vesicles were dissected and their wet weights were recorded. In groups that received either
A10-Nano-ARHP8 or naked ARHP8 NPs, prostate wet weight was significantly lower than
that in A10-Nano-GFP-treated animals (Figure 2B), suggesting that ARHP8 NPs reduced
tumor growth. RT-PCR analysis revealed that treatment with A10-Nano-ARHP8 NPs
dramatically reduced AR gene expression compared with the control group, although Nano-
ARHP8 also moderately reduced AR gene level (Figure 2C). These data were supported by
the results from in vitro cell culture-based experiments (Figure 5) and our previous animal
studies with AAV approach [13], indicating that PLGA NPs loaded with ARHP8 constructs
induced AR gene silencing and that A10 conjugation enhanced the effect of ARHP8-loaded
PLGA NPs on AR gene silencing in vivo.
Finally, we analyzed the copy numbers of ARHP8 constructs in xenograft tumor tissues.
Genomic DNA samples were extracted from tumor tissues of LNCaP and 22RV1 xenografts
obtained from the subcutaneous xenograft models (Figures 1A & 1C). Quantitative PCR
assays were conducted to assess the DNA content of GFP sequence derived from the
plasmid construct. Serially diluted samples of GFP-ARHP8 construct were used to generate
the quantitative PCR standard curve. As shown in Figure 7A, a linear curve was obtained by
plotting the quantitative PCR results with the concentrations of GFP-ARHP8 plasmid
constructs. Consistent with the antitumor effect, in both LNCaP and 22RV1 xenografts,
A10-conjugated NPs yielded a much higher DNA content in xenograft tumors than
nonconjugated NPs (Figure 7B). Together with other results from Figures 1A, 2A, 4 & 5,
our study clearly confirmed the notion that PSMA A10 conjugation enhances PLGA NP
retention in prostate cancer cells compared with the naked ones.
Discussion
In this study, we continued our previous work of AR siRNA-based gene therapy for prostate
cancers [7,13]. The biodegradable PLGA polymer-based NPs were utilized to deliver the
AR shRNA constructs and prostate cancer-specific targeting was achieved by conjugating
the NP surface with PSMA A10 aptamers. Our cell culture- and xenograft-based testing
revealed that PLGA-mediated delivery of AR shRNA constructs yielded an effective AR
gene silencing and A10 conjugation largely enhanced the antitumor effect of AR shRNA
NPs. These results strongly suggest that the A10-conjugated ARHP8 construct-loaded
PLGA NP represents a novel gene therapy for prostate cancers.
Recently, PLGA NPs were widely used for drug delivery studies [40–42]. Our previous
work illustrated the advantages of monodisperse particles in controlling the release kinetics
of drugs from the polymer matrix [36–38]. Our recent studies also indicated that particle size
can be optimized for different delivery purposes and plasmid DNA constructs can be
encapsulated without any damage [43]. In this study, our data further confirmed that the
solvent diffusion method for PLGA NP fabrication retained DNA function.
The RNA aptamer A10 is a ligand for PSMA and was widely used to achieve prostate-
specific targeting [21]. The A10 aptamer has been used to conjugate with various NPs for
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targeted chemotherapy [25–30] and molecular imaging [31,32], or to form chimeras with
shRNA constructs for targeted gene therapy [33,34]. In this study, we used a PEG-spacer
(the hydrophilic blocks of Pluronic F127) to conjugate the A10 onto the NPs. The carboxylic
acid end group of modified Pluronic F127-COOH on the surface of PLGA NPs was
conjugated to an amine-modified version of the A10 aptamer. The purpose of the PEG
spacer was to avoid absorption of blood proteins and extend NP circulation.
The key component of the NP is the AR silencing construct, which is a plasmid vector that
bears a hairpin-structured siRNA sequence against the human AR gene. This construct,
pU6-ARHP8-hGFP, were used to generate AAV particles that was previously proven to
effectively silence the AR gene in prostate cancer cells [7] and xenograft tumor regression in
mice [13]. This construct carries a secondary coding sequence for humanized GFP protein
linked by a polivirus IRES sequence after the ARHP8 cassette, providing the extra feature of
a GFP marker for monitoring tissue distribution of the NPs. Our results with the Nano-
ARHP8 approach in this study were comparable to our previously reported AAV approach
[13], leading to xenograft regression within 2 weeks of treatment. However, PLGA NPs
have multiple advantages over viral vectors, such as biodegradability, surface conjugation of
targeting moieties, possible loading of multiple components, the possibility of limited
toxicity or immunogenicity. In addition, A10 conjugation provided superb efficacy over the
naked NP, as evidenced by a quicker recession of xenograft tumors.
In conclusion, we developed a novel strategy of PSMA-targeted NPs loaded with AR
shRNA constructs for prostate cancer gene therapy. The NPs were fabricated with
biodegradable PLGA polymers, whose surfaces were conjugated with PSMA aptamer A10
as the targeting moiety. Our in vitro and in vivo testing demonstrated that ARHP8-loaded
PLGA NPs mediated AR gene silencing in vitro and in vivo, and that A10 conjugation
enhanced cellular uptake of ARHP8-loaded NPs. Upon systemic delivery of the ARHP8-
loaded NPs, rapid PSA decline and tumor regression were observed in 2 weeks. In addition,
A10 conjugation enhanced PSA decline and xenograft tumor regression compared with
nonconjugated NPs. Prostate-specific delivery of ARHP8 shRNA constructs using
biodegradable NPs represents a novel therapy for prostate cancers with efficacy rivaling our
prior studies employing viral vectors.
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▪ Biodegradable poly-DL-lactic-co-glycolic acid polymer-based nanoparticles
can be used to encapsulate androgen receptor (AR) shRNA constructs.
▪ Surface conjugation of prostate-specific membrane antigen aptamer A10
enhanced cellular uptake of nanoparticles in vitro and in vivo.
▪ AR shRNA-loaded nanoparticles led to rapid tumor regression.
▪ Prostate-specific membrane antigen A10 mediated prostate-specific delivery
of poly-DL-lactic-co-glycolic acid nanoparticles loaded with AR shRNA
represents a novel therapy for prostate cancers.
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Figure 1. ARHP8 nanoparticles induce xenograft tumor eradication in nude mice
(A) Xenograft tumors were established in nude mice with 22RV1, (B) LAPC-4 or (C)
LNCaP cells. Once tumors were palpable (~30–50 mm3 in volume), animals were divided
into different groups to receive various nanoparticles (n = 8). Nanoparticles were injected
via tail vein in a volume of 200 µl that contains 4.0 µg plasmid DNA. A second dose was
delivered in 1 week. Animals were monitored for tumor growth for 3 weeks. Data shows the
average value of relative tumor volume (%) at the measuring time-point compared with the
initial size at the first nanoparticle injection. Error bars represent the standard error of the
mean. The vertical axis is in log scale.
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*Significant difference compared with the control (p < 0.05, Student’s t-test).
GFP: Green fluorescent protein.
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Figure 2. ARHP8 nanoparticles reduces serum prostate-specific antigen levels in nude mice
Orthotopic xenograft tumors were established in nude mice with LNCaP cells by inoculating
2 × 105 cells in 10 µl volume of culture media. Blood samples were collected through tail
incision and serum PSA levels were monitored every week. Once serum PSA levels reached
70–90 ng/ml, animals were divided into three groups (n = 8) to receive different
nanoparticles. Nanoparticles were injected via tail vein in a volume of 200 µl that contains
4.0 µg plasmid DNA. A second dose was delivered in 1 week. Animals were monitored for
PSA levels for another 3 weeks. (A) Data shows the average value of serum PSA and the
standard error of the mean. (B) Mouse prostate loops were harvested at sacrifice and the wet
Yang et al. Page 15













weight was recorded. (C) Total RNAs were extracted from frozen tissue samples of the
prostate loops and reverse transcription-PCR analysis was conducted to assess the AR gene
expression.
*A significant difference compared with the control (p < 0.05, Student’s t-test).
AR: Androgen receptor; GFP: Green fluorescent protein; PSA: Prostate-specific antigen.
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Figure 3. Nanoparticle-aptamer bioconjugation
(A) PLGA nanoparticles were modified by covalent conjugation with a PEG spacer. The
RNA aptamer A10 that recognizes the human PSMA extracellular domain was conjugated
onto the PEG spacer. (B) Confirmation of aptamer conjugation onto nanoparticles. Agarose
gel image of plasmid DNA and A10 aptamer extracted from different nanoparticles.
GFP: Green fluorescent protein; M: Marker; PEG: Polyethylene glycol; PLGA: Poly-DL-
lactic-co-glycolic acid; PSMA: Prostate-specific membrane antigen.
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Figure 4. Cellular uptake of nanoparticles with or without A10 Aptamer
(A) Different amounts of nanoparticle loaded with Nile-red fluorescent dye were added to
LNCaP cell culture media and 1 h later, cells were stained with blue nuclear dye Hoechst
33324. Quantitative data were summarized in panel (B) and error bars represent the standard
error of the mean. (C) A total of 3 µl nanoparticles were added in cell culture for the
indicated time period and the cell nuclei were visualized with Hoechst 33324 staining. (D)
Tumor uptake of nanoparticles in vivo. 22RV1-derived xenografts were established in nude
mice, and 150 µl nanoparticles were injected via tail vein. Xenografts were harvested at
indicated time points after injection. Frozen sections were prepared and the cell nuclear
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DNA was stained with 4’,6-diamidino-2-phenylindole. Sections were evaluated under a
fluorescent microscope.
Magnification ×200.
*Significant difference compared with the control (p < 0.01, student’s t-test).
Yang et al. Page 19













Figure 5. ARHP8-loaded nanoparticle-mediated AR gene silencing
(A) LNCaP or (B) LAPC-4 cells were placed in six-well plates overnight and then different
nanoparticles were added into cell culture media at a dose of 2 µg DNA/well. Cells were
harvested 7 days later and the total RNAs were extracted for RT-PCR and the S18 gene was
used as an internal control. Cell lysates were used in western blot assays and anti-Actin blot
served as protein loading control. (C) Total RNAs from panel (A) and (B) were used for
quantitative RT-PCR to assess AR gene expression. Error bars represents the standard error
of the mean.
*Significant difference compared with the control (p < 0.05, Student’s t-test).
AR: Androgen receptor; GFP: Green fluorescent protein; RT-PCR: Reverse transcription-
PCR.
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Figure 6. Pilot experiment for dose determination of ARHP8 nanoparticle-mediated AR gene
silencing
Xenograft tumors were established in nude mice with human prostate cancer cells PC-3/AR.
Once tumors were palpable (~30–50 mm3 in volume), Nano-ARHP8 nanoparticles were
injected via tail vein. A total of five different doses were used. One animal was injected with
PBS as a negative control. After 1 week, animals were sacrificed and xenograft tumors,
together with various major organs, were harvested for further analysis. (A) Total RNAs
were extracted for reverse transcription-PCR analysis for AR mRNA and GFP mRNA
expression. S18 was used as an internal control. (B) Protein extracts were prepared from
xenograft tumors and probed with anti-AR antibody for AR protein levels. Actin blot served
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as a loading control. (C) Genomic DNA extracts from xenograft tumor and major organs of
the animal were used as templates in the PCR reaction to detect GFP sequence on the
ARHP8 shRNA vector for the purpose of nanoparticle distribution.
AR: Androgen receptor; GFP: Green fluorescent protein; PBS: Phosphate-buffered saline.
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Figure 7. Prostate-specific membrane antigen A10 conjugation increases nanoparticle retention
in prostate cancer xenografts
(A) The qPCR standard curve was generated using a serially diluted ARHP8-GFP construct
as a template. (B) Genomic DNA samples were extracted from xenograft ssmples derived
from 22RV1 and LNCaP cells as described in Figure 1 and used for quantitative PCR
analysis of GFP expression. The relative construct copy numbers in the tissue were
calculated based on the molecular weight of the ARHP8-GFP plasmid construct.
*A significant difference in A10-Nano-ARHP8 groups compared with the nonconjugated
Nano-ARHP8 group (n = 4, p < 0.05, Student’s t-test).
GFP: Green fluorescent protein; qPCR: Quantitative PCR.
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Table 1
Characteristics of poly-DL-lactic-co-glycolic acid nanoparticles.
Nanoparticles Nano-GFP A10-Nano-GFP Nano-ARHP8 A10-Nano-ARHP8
Size ± SD (nm) 244 ± 1.9 244 ± 4.1 185 ± 0.5 185 ± 0.1
Polydispersity 0.27 ± 0.01 0.26 ± 0.01 0.11 ± 0.04 0.17 ± 0.01
Zeta potential ± SD (mV) −16.1 ± 1.95 −16.3 ± 0.91 −25.4 ± 0.66 −24.8 ± 0.52
Plasmid DNA loading (µg/ml) 20 20 21 21
Encapsulation efficiency (%) 93.1 ± 1.5 84.1 ± 1.4 72.6 ± 1.8 73.5 ± 1.8
Total surface area (m2/g PLGA) 18.4 18.4 24.2 24.2
Surface aptamer (pMol/cm2) N/A 5.8 N/A 4.6
a
GFP: Green fluorescent protein; N/A: Not applicable; PLGA: Poly-DL-lactic-co-glycolic acid; SD: Standard deviation.
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